Barrie, Ontario – When Cannabis became legal in Canada in 2018, supply and demand were the main news flash points.
The other story was, can this be a sustainable industry on the financial docket.
MediPharm Labs Corp., Canada’s current leader in purified cannabis extraction, announced preliminary revenue for Q4, 2018: $10 million in sales for their first operating quarter, weeks after the company received its Health Canada sales licence on November 12th, 2018.
MediPharm is fully licensed under the Cannabis Act (Canada) focused on downstream secondary extraction methodology, distillation, and cannabinoid isolation and purification, is pleased to announce it has signed three cannabis oil sales agreements, subsequent to the Company’s receipt of its sales license from Health Canada on November 9, 2018. The first large shipments of cannabis oil supply left the Company’s dock in December 2018 and were aggregately valued at over $10 million.
Courtesy MediPharm, December sales performance (see peer comparison chart below) MediPharm has demonstrated its strong potential to rank among the top companies in the Cannabis industry.
| Market Cap – Jan 17/19 | Licensed Producer | Reported Revenue Latest quarter CAD | Reported Sales (kg) Latest quarter | Period Reported |
| $19.7 B | Canopy Growth | $23.3 million | 2,197 | Q2/19 (Q ended Sept 30, 2018) |
| $8.2 B | Aurora | $24.6 million (cannabis revenue only) | 2,676 | Q1/19 (Q ended Sept 30, 2018) |
| $2.1 B | Aphria | $21.7 million | 3,408kg | (Q ended Nov 30, 2018) |
| $7.3 B (US) | Tilray | $12.6 million | 1,613kg | (Q ended Sept 30, 2018) |
| $3.48B | Cronos | $3.7 million | 397kg dry cannabis | (Q ended Sept 30, 2018 |
| $812 M | Organigram | $3.2 million | 200,310 grams sold | Q4 2018 (Q ended Aug 31, 2018) |
| $200M | MediPharm Labs | $10 million | Purchased 1,600KG between December 18/18 – Jan 8/19 | December 2018 sales (one month only) |
